EUVIMEDEUVIMED entdecken
Fallbericht

Successful treatment of bullous lupus with corticosteroids and belimumab: A case report

Chandana Keshavamurthy, Emily Fibeger, Andrew Virata, Pankaj Bansal iD

Modern Rheumatology Case Reports · 2023

DOI: 10.1093/mrcr/rxac046 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2023. Verfasst von Chandana Keshavamurthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ochsner Medical Center, New Orleans, LA, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous lupus erythematosus (CLE) is one of the most common manifestations of systemic lupus erythematosus (SLE), although it can manifest as an independent entity as well. Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous manifestation of SLE presenting as tense vesiculobullous eruptions in a photosensitive distribution. Pathophysiology is secondary to autoantibodies against noncollagenous domain 1 and 2 (NC1 and NC2) type VII collagen, and histopathology reveals dense neutrophilic infiltration of the dermis with direct immunofluorescence showing IgG deposition at dermoepidermal junction. There is lack of data on available therapeutic options to treat BSLE, and varying responses to dapsone, methotrexate, azathioprine and corticosteroids have been reported. Belimumab, a fully humanised Change to Immunoglobulin G1λ (IgG1λ) monoclonal antibody targeting soluble B lymphocyte stimulator protein, was the first Food and Drug Administration-approved drug for SLE and has been reported to be effective for CLE. We present the case of a 41-year-old black female with SLE presenting with BSLE, who was successfully treated with corticosteroids and belimumab and did not experience disease relapse even after discontinuation of corticosteroids. To our knowledge, this is the first reported case of successful treatment of BSLE with belimumab, and further research can help determine the role of belimumab in the treatment of BSLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus Erythematosus, CutaneousUnited StatesFemaleHumansAdultAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAzathioprine

Stichwörter der Autor:innen

Lupusbelimumab

Substanzen

belimumabAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAzathioprine

Autor:innen und Institutionen

  • Department of Rheumatology, Ochsner Medical Center, New Orleans, LA, USA.
  • Department of Dermatology, Mayo Clinic Health System, Eau Claire, WI, USA.
  • Department of Dermatopathology, Tareen Dermatology, Roseville, MN, USA.
  • Department of Rheumatology, Mayo Clinic Health System, Eau Claire, WI, USA.

ORCID-Profile: Pankaj Bansal

Zitieren

APA

Keshavamurthy, C., Fibeger, E., Virata, A., & Bansal, P. (2023). Successful treatment of bullous lupus with corticosteroids and belimumab: A case report. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxac046

Vancouver

Keshavamurthy C, Fibeger E, Virata A, Bansal P. Successful treatment of bullous lupus with corticosteroids and belimumab: A case report. Modern Rheumatology Case Reports. 2023. doi:10.1093/mrcr/rxac046

BibTeX
@article{Keshavamurthy2023,
  author = {Keshavamurthy, Chandana and Fibeger, Emily and Virata, Andrew and Bansal, Pankaj},
  title = {Successful treatment of bullous lupus with corticosteroids and belimumab: A case report},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  doi = {10.1093/mrcr/rxac046}
}
Kostenlos starten →